Hepatitis B virus surface antigen 183–191 peptide–HLA-A2 complex

The hepatitis B virus surface antigen 183–191 peptide–HLA-A2 complex comprises an epitope (commonly sequence FLLTRILTI, with possible R187K mutation) derived from the hepatitis B surface antigen, which is presented by the human leukocyte antigen HLA-A2 (a major histocompatibility complex class I molecule). This complex is recognized by cytotoxic T lymphocytes, playing a major role in anti-HBV immunity by allowing immune cells to detect and kill infected hepatocytes. Variants of this peptide (such as K187 mutations) retain HLA-A2 binding and immunogenicity, highlighting the target’s relevance across genetically diverse patient populations. The study and engineering of such complexes inform vaccine and immunotherapy development against HBV[1]. Note: There is no universally recognized shorter abbreviation or standardized gene/protein designation for this specific peptide-HLA complex in canonical databases — it is typically described by its peptide sequence and MHC allele[1].

Other names

HBsAg183–191–HLA-A2 complexHepatitis B surface antigen 183–191 epitope–HLA-A2 complexFLLTRILTI–HLA-A2 complexR187 peptide–HLA-A2 complex

Induction of CTL-mediated immune response via presentation of viral peptide to CD8+ T cells. Peptide vaccines: stimulate antigen-specific T cell responses by mimicking natural viral antigen presentation.